FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1048972321> ?p ?o ?g. }

• W1048972321 endingPage "660" @default.
• W1048972321 startingPage "650" @default.
• W1048972321 abstract "Health insurance administrative claims databases represent a valuable source of information regarding the safety profile of marketed products as used in actual clinical practice in a broader range of patients than that assessed in clinical trials. Interferon beta-1a administered subcutaneously 3 times weekly (IFN β-1a SC tiw), which was approved in 2002 by the FDA for the treatment of relapsing-remitting multiple sclerosis (MS), has over a decade of postmarketing experience. To date, however, its postmarketing safety profile has not been described using a real-world evidence source such as administrative claims data.To describe the safety profile of IFN β-1a SC tiw as presented in its U.S. prescribing information (PI) for patients with MS initiating IFN β-1a SC tiw therapy using data from U.S. health care administrative claims databases.This study featured an observational and retrospective new start cohort design using data from the Truven MarketScan Commercial and Medicare Supplemental health care administrative claims databases. Patients were eligible for inclusion if they were aged ≥ 18 years; had ≥ 1 diagnosis for MS recorded between January 1, 2006, and December 31, 2012; had ≥ 2 prescriptions for IFN β-1a SC tiw; and had ≥ 90 days of continuous eligibility pre-index date and ≥ 180 days of continuous eligibility post-index date. Patients with a prescription for IFN β-1a SC tiw without a MS diagnosis were excluded. Patients were followed from first prescription for IFN β-1a SC tiw (index date) until date of therapy switch or discontinuation, end of insurance eligibility, or end of observation period. Adverse events (AEs) examined were those listed in the Warnings and Precautions, Adverse Reactions, and Postmarketing Experience sections of the 2014 U.S. PI. Outcomes of interest were identified at the Medical Dictionary for Regulatory Activities (version 17.1) Preferred Term level and then coded to the corresponding ICD-9-CM criteria. Descriptive analyses of patient demographic, health status, health care utilization, and adherence status were performed, and incidence rates (IRs) per 100 person-years of labeled AEs with corresponding 95% CIs were calculated. The IR calculation was based on events that presented after therapy initiation and that were not present in the 90-day pre-index period.The top 6 AEs included influenza-like symptoms (IR = 15.65, 95% CI = 14.96-16.36); malaise (IR = 15.33, 95% CI = 14.65-16.04; fatigue (IR = 15.02, 95% CI = 14.35-15.72); abdominal pain (IR = 10.18, 95% CI = 9.67-10.70); chest pain (IR = 8.48, 95% CI = 8.03-8.95); and depression (IR = 7.75, 95% CI = 7.32-8.20). In contrast, the 6 lowest IRs were for maculo-papular rash (IR = 0.01, 95% CI = 0.00-0.04; injection-site necrosis (IR = 0.01, 95% CI = 0.00-0.03); erythema multiforme (IR = 0.01, 95% CI = 0.00-0.04); hypoesthesia (IR = 0.00, 95% CI = 0.00-0.02); Stevens-Johnson Syndrome (IR = 0.00, 95% CI = 0.00-0.02); and xerophthalmia (IR = 0.00, 95% CI = 0.00-0.02).Study results show strong convergence between the real-world safety profile of IFN β-1a SC tiw and its U.S. label. Our findings demonstrate the value of using real-world evidence obtained from administrative claims to complement clinical trial and postmarketing surveillance data in order to characterize the safety profile of established products, such as IFN β-1a SC tiw, in the postmarketing context." @default.
• W1048972321 created "2016-06-24" @default.
• W1048972321 creator A5008221964 @default.
• W1048972321 creator A5025469994 @default.
• W1048972321 creator A5028436742 @default.
• W1048972321 creator A5039246451 @default.
• W1048972321 creator A5061867311 @default.
• W1048972321 creator A5068315063 @default.
• W1048972321 creator A5077653595 @default.
• W1048972321 date "2015-08-01" @default.
• W1048972321 modified "2023-10-18" @default.
• W1048972321 title "Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis" @default.
• W1048972321 cites W1502925188 @default.
• W1048972321 cites W1529192025 @default.
• W1048972321 cites W1970190011 @default.
• W1048972321 cites W1983999022 @default.
• W1048972321 cites W2002097738 @default.
• W1048972321 cites W2008369480 @default.
• W1048972321 cites W2014094373 @default.
• W1048972321 cites W2020586520 @default.
• W1048972321 cites W2022714644 @default.
• W1048972321 cites W2023130746 @default.
• W1048972321 cites W2031915800 @default.
• W1048972321 cites W2049566645 @default.
• W1048972321 cites W2055764278 @default.
• W1048972321 cites W2057112394 @default.
• W1048972321 cites W2080458330 @default.
• W1048972321 cites W2080543874 @default.
• W1048972321 cites W2087836606 @default.
• W1048972321 cites W2092276202 @default.
• W1048972321 cites W2093042928 @default.
• W1048972321 cites W2095037231 @default.
• W1048972321 cites W2105477343 @default.
• W1048972321 cites W2105823731 @default.
• W1048972321 cites W2123700459 @default.
• W1048972321 cites W2125854622 @default.
• W1048972321 cites W2132555717 @default.
• W1048972321 cites W2145920263 @default.
• W1048972321 cites W2148814846 @default.
• W1048972321 cites W2150487817 @default.
• W1048972321 cites W2154692607 @default.
• W1048972321 cites W2158488354 @default.
• W1048972321 cites W2169098250 @default.
• W1048972321 cites W2319434003 @default.
• W1048972321 cites W2324187974 @default.
• W1048972321 cites W2334875480 @default.
• W1048972321 doi "https://doi.org/10.18553/jmcp.2015.21.8.650" @default.
• W1048972321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26233537" @default.
• W1048972321 hasPublicationYear "2015" @default.
• W1048972321 type Work @default.
• W1048972321 sameAs 1048972321 @default.
• W1048972321 citedByCount "14" @default.
• W1048972321 countsByYear W10489723212016 @default.
• W1048972321 countsByYear W10489723212017 @default.
• W1048972321 countsByYear W10489723212018 @default.
• W1048972321 countsByYear W10489723212019 @default.
• W1048972321 countsByYear W10489723212020 @default.
• W1048972321 countsByYear W10489723212021 @default.
• W1048972321 crossrefType "journal-article" @default.
• W1048972321 hasAuthorship W1048972321A5008221964 @default.
• W1048972321 hasAuthorship W1048972321A5025469994 @default.
• W1048972321 hasAuthorship W1048972321A5028436742 @default.
• W1048972321 hasAuthorship W1048972321A5039246451 @default.
• W1048972321 hasAuthorship W1048972321A5061867311 @default.
• W1048972321 hasAuthorship W1048972321A5068315063 @default.
• W1048972321 hasAuthorship W1048972321A5077653595 @default.
• W1048972321 hasBestOaLocation W10489723211 @default.
• W1048972321 hasConcept C126322002 @default.
• W1048972321 hasConcept C160735492 @default.
• W1048972321 hasConcept C162324750 @default.
• W1048972321 hasConcept C167135981 @default.
• W1048972321 hasConcept C187212893 @default.
• W1048972321 hasConcept C194828623 @default.
• W1048972321 hasConcept C197636746 @default.
• W1048972321 hasConcept C197934379 @default.
• W1048972321 hasConcept C2426938 @default.
• W1048972321 hasConcept C2778715236 @default.
• W1048972321 hasConcept C50522688 @default.
• W1048972321 hasConcept C512399662 @default.
• W1048972321 hasConcept C71924100 @default.
• W1048972321 hasConcept C98274493 @default.
• W1048972321 hasConceptScore W1048972321C126322002 @default.
• W1048972321 hasConceptScore W1048972321C160735492 @default.
• W1048972321 hasConceptScore W1048972321C162324750 @default.
• W1048972321 hasConceptScore W1048972321C167135981 @default.
• W1048972321 hasConceptScore W1048972321C187212893 @default.
• W1048972321 hasConceptScore W1048972321C194828623 @default.
• W1048972321 hasConceptScore W1048972321C197636746 @default.
• W1048972321 hasConceptScore W1048972321C197934379 @default.
• W1048972321 hasConceptScore W1048972321C2426938 @default.
• W1048972321 hasConceptScore W1048972321C2778715236 @default.
• W1048972321 hasConceptScore W1048972321C50522688 @default.
• W1048972321 hasConceptScore W1048972321C512399662 @default.
• W1048972321 hasConceptScore W1048972321C71924100 @default.
• W1048972321 hasConceptScore W1048972321C98274493 @default.
• W1048972321 hasIssue "8" @default.
• W1048972321 hasLocation W10489723211 @default.
• W1048972321 hasLocation W10489723212 @default.

• next